linjc16/ctgov huggingface dataset:
Large Scale ICU Data Sharing for 1000 Critically Ill Patients With Severe Acute Respiratory Distress Syndrome Coronavirus (SARS.COV19) in Three Distinct Isolation Centers

Study Overview
=================
Brief Summary
-----------------
Cohort study of patients with severe respiratory distress syndrome coronavirus2 in three different isolation hospitals recording data about outcome.

Official Title
-----------------
Large Scale ICU Data Sharing for 1000 Critically Ill Patients With Severe Respiratory Distress Syndrome Coronavirus in Three Distinct Isolation Centers

Conditions
-----------------
Median Nerve Entrapement

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All COVID positive candidates Exclusion Criteria: patient refusal

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| follow up | mortality, length of ICU stay, ( days) | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prediction | prediction of mortality and morbidity | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
neuropathy
Belfort Dildy- Obstetrical Tamponade System Post-Marketing Surveillance Program

Study Overview
=================
Brief Summary
-----------------
This is an open, post-marketing surveillance study obtaining data retrospectively on 300 women, of any age, treated with the BD-OTS for postpartum uterine bleeding.

Official Title
-----------------
Belfort Dildy- Obstetrical Tamponade System Post-Marketing Surveillance Program

Conditions
-----------------
Postpartum Uterine Bleeding

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Treatment with the BD-OTS device Exclusion Criteria: None
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Belfort-Dildy Obstetric Tamponade Tx<br>Patients treated with Belfort-Dildy Obstetric Tamponade System are eligible for inclusion in the cohort. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to demonstrate the safety of the gynecological formulation in normal and usual usage condition of Dermacyd Tina Gel Sweet Flower.

Official Title
-----------------
Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower

Conditions
-----------------
Hygiene

Intervention / Treatment
-----------------
* Drug: Lactic acid (Dermacid)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Integral skin test in the region; Exclusion Criteria: Lactation or gestational risk or gestation; Use of Anti-inflammatory or immunosuppression drugs 1 month before the study; Topical medication use at the region to be treated; Cutaneous disease or active gynecological disease which may interfere in study results; Personal history of allergic disease at the area to be treated; Allergic or atopic history; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Lactic acid in small quantity during 21 days. | Drug: Lactic acid (Dermacid)<br>* Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events and their intensity and their association with the treatment. |  | 21 days |
Effect of Dynamic Light Application on Performance of ICU Nurses

Study Overview
=================
Brief Summary
-----------------
In two sessions of four days nurses will be exposed to dynamic lighting and normal (reference) lighting. Through the psychological tests T.O.D.A. (Test or divided attention) and T.O.S.S.A. (Test of sustained selective attention), then the focus tested. These two tests run both 5 times. The investigators also ask to fill out: 3 questionnaires, fatigue and mood, sleep and Questions of Life.

Official Title
-----------------
Effect of Dynamic Light Application on Performance of ICU Nurses

Conditions
-----------------
Sustained Selective Attention, Divided Attention

Intervention / Treatment
-----------------
* Other: dynamic light


Participation Criteria
=================
Eligibility Criteria
-----------------
ICU nurses working 32 hours/week or more

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: dynamic light<br>dynamic light | Other: dynamic light<br> <br> |
| No Intervention: reference<br>normal light | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| score on Test of Divided Attention | divided attention | march 2013 | 
| Test on Sustained Selective Attention(TOSSA) |  | to april 2013 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dynamic light application, sustained attention, divided attention, nursing
The Effect of Different Emergency Medical Systems on the Prognosis of Traumatic Brain Injury - a Prospective Study

Study Overview
=================
Brief Summary
-----------------
The Aim of the Study is to Measure the Effect of Finnish Physician-staffed EMS Unit Treatment Methods on Traumatic Brain Injury (TBI) Patient Prognosis. Physician-staffed HEMS unit was implemented to the EMS 2011. The aim of this study is to compare the results against a historical database to see if the implementation of a HEMS unit will improve the prognosis of TBI patients.

Detailed Description
-----------------
A Secondary Aim is to Identify Out-of-hospital Treatment Factors That Can be Influenced by Education and Protocols.

Official Title
-----------------
The Differences Between Out-of-hospital Severe Traumatic Brain Injury (TBI) Treatment in a Physician-staffed Versus Paramedic-staffed Emergency Medical Service (EMS) Unit and Its Effect on Patient Prognosis

Conditions
-----------------
Traumatic Brain Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: TBI with CGS < 9 or unconsciousness verified by an on-call neurosurgeon during admission to the hospital. Exclusion Criteria: Multiple trauma
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| FinnHEMS10<br>Patients Treated by Helsinki HEMS. | |
| FinnHEMS30<br>PAtients Treated by Tampere HEMS. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glasgow Outcome Score |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Traumatic Brain Injury, HEMS, Out-of-hospital, Finland
Can Kangarooing Small Babies on the Back of a Mother Keep Them Warm and Stable

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to assess the effectiveness of Kangarooing small babies on the back of a mother

Detailed Description
-----------------
After the study was explained (risks and benefits) and written informed consent was received from participants, an individually controlled randomized crossover clinical trial was conducted to examine the effectiveness of Chest-to-Back (CB) skin-to-skin contact (SSC) compared with the standard. The trial was done in accordance with the protocol, good clinical practice, and the national regulatory and ethics guideline of Ethiopia (which is in line with the Helsinki declaration).

Official Title
-----------------
The Effect of Chest-to-Back Skin-to-Skin Contact on Regulation of Physiological Parameters for Low Birth Weight and/or Premature Infants: a Crossover Randomized Controlled Clinical Trial

Conditions
-----------------
Body Temperature, Oxygen Saturation, Heart Rate, Respiratory Rate, Sleep Pattern

Intervention / Treatment
-----------------
* Other: Chest-to-back


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Neonates with LBW (<2500 grams) Born prematurely (< 37 complete weeks of gestation) Exclusion Criteria: less than 35 weeks of gestation on the day of enrollment to trial Malformations or birth disabilities Dependent on oxygen or IV fluid Any disorder that was deemed necessary for exclusion by the investigator.

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 28 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CB-SSC<br>The participant received CB-SSC for 2 hours per day for three consecutive days | Other: Chest-to-back<br> <br> * Other names: The standard/or Chest-to-chest;|
| Placebo Comparator: CC-SSC<br>Following a 30 minute washout time, the same participant would continue to receive chest-to-chest (CC) SSC for 2 hours. This was also conducted for three consecutive days | Other: Chest-to-back<br> <br> * Other names: The standard/or Chest-to-chest;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in skin temperature from baseline | Skin temperature values were recorded every 10 minutes. Including the baseline, the 2 hours intervention would provide 13 measurements. A participant who successfully completed the intervention would have78 measurements; 39 for the treatment arm and 39 for the control arm. | : From the start of SSC (0 hour) to end of SSC (2 hours) per day, assessed for three consecutive days |
AI Colorectal Polyp Detection

Study Overview
=================
Brief Summary
-----------------
This study is intended to demonstrate the superiority of colorectal polyp detection using computer-assisted colonoscopy compared to conventional colonoscopy.

Official Title
-----------------
Colorectal Polyp Detection Comparing Computer Assisted Colonoscopy With Conventional Colonoscopy

Conditions
-----------------
Polyp Colorectal, Adenoma Colon

Intervention / Treatment
-----------------
* Device: EW10-EC02 (Endoscopy Support Program)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Average risk subjects undergoing their first colonoscopy (screening) or follow-up colonoscopy for previous history of polyps (surveillance interval of 3 years or greater) Patients aged 45 or older Patients who can provide an informed consent Exclusion Criteria: Patients with history of colon resection, Inflammatory Bowel Disease (IBD), Familial Adenomatous Polyposis (FAP), severe comorbidity, including end-stage cardiovascular/pulmonary/liver/renal disease Patients who are pregnant or are planning pregnancy during study period Patients who are not able to or refuse to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CAC Group<br>Inspection with computer assisted colonoscopy. | Device: EW10-EC02 (Endoscopy Support Program)<br>* EW10-EC02 is intended to automatically detect the location of suspected polyps in colonoscopy exams. Identified polyps are highlighted to the clinician in real-time during the exam, as a video image superimposed on the endoscope monitor. EW10-EC02 is limited to the detection of suspected findings, and should not be used in lieu of full patient evaluation or relied upon to make or confirm a diagnosis.<br>|
| No Intervention: CC Group<br>Inspection with conventional colonoscopy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adenoma per colonoscopy (APC) | Total number of histologically confirmed adenomas and carcinomas detected in the colonoscopy divided by the total number of colonoscopies | 1 day/procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Positive predictive value (PPV) | Total number of histologically confirmed adenomas and carcinomas detected during the colonoscopy, divided by the total number of excisions in the colonoscopy | 1 day/procedure | 
| Adenoma detection rate (ADR) | proportion of patients with at least one histologically confirmed adenoma or carcinoma detected in the colonoscopy | 1 day/procedure |
A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and efficacy of the iStent trabecular micro-bypass stent in reducing intraocular pressure (IOP) in subjects with open-angle glaucoma.

Detailed Description
-----------------
The study compares 1 stent versus 2 stents.

Official Title
-----------------
A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2 Stents

Conditions
-----------------
Open-Angle Glaucoma

Intervention / Treatment
-----------------
* Device: Stent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with open-angle glaucoma (OAG) Subject on at least one glaucoma medication Signed informed consent Exclusion Criteria: Angle closure glaucoma Secondary glaucomas except pseudoexfoliative and pigmentary; no neovascular, uveitic or angle recession glaucoma Prior glaucoma procedures (eg trabeculectomy, viscocanalostomy, ALT, SLT, shunt implant, collagen implant, cyclo destructive procedures etc) Fellow eye already enrolled

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br> | Device: Stent<br>* implantation of 1 Glaukos iStent versus 2 Glaukos iStents<br>* Other names: iStent;|
| Active Comparator: 2<br> | Device: Stent<br>* implantation of 1 Glaukos iStent versus 2 Glaukos iStents<br>* Other names: iStent;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy |  | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Open angle, Glaucoma, Surgery
Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Japan. The purpose of this trial is to investigate the safety and the effect of biphasic insulin aspart 50 compared to biphasic human insulin 50 in patients with type 2 diabetes mellitus.

Official Title
-----------------
Safety and Effect of Biphasic Insulin Aspart 50 Compared to Biphasic Human Insulin 50 in Patients With Type 2 Diabetes Mellitus.

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: biphasic insulin aspart
* Drug: biphasic human insulin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes mellitus Current treatment with pre-mixed human insulin preparation or biphasic/pre-mixed insulin analogue in twice daily treatment for at least 8 weeks. HbA1C: less than 11.0% BMI: less than 30.0 kg/m2 Exclusion Criteria: Total daily insulin dose: 100 IU/U and more Treatment with oral hypoglycaemic agents within the last 4 weeks. Treatment with insulin sensitizer within the last 12 weeks A lifestyle that is considered unsuitable for this trial (frequent or routine night shift workers etc.)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: biphasic insulin aspart|nan|
|Drug: biphasic human insulin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of hypoglycaemic episodes |  | During 16 weeks of treatment |
Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia

Study Overview
=================
Brief Summary
-----------------
Study to describe Tamsulosin prescription characteristics in a representative population of patients on treatment for benign prostatic hyperplasia

Official Title
-----------------
Observational Study About the Use of Tamsulosin in Patients With Benign Prostatic Hyperplasia

Conditions
-----------------
Prostatic Hyperplasia

Intervention / Treatment
-----------------
* Drug: Tamsulosin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 21 years old diagnosed with benign prostatic hyperplasia (BPH), who require pharmacological treatment to relieve symptoms and improve their quality of life, according to physician's judgment. The study will include naïve patients and patients not responding to previous therapy who receive Secotex as alternative or complementary treatment. The decision to treat a patient with Tamsulosin must be based on the best standard accepted in the clinical practice and must be carried out following Secotex (Tamsulosin) prescription information Exclusion Criteria: Patients with known hypersensitivity to Tamsulosin or any of its ingredients, history of orthostatic hypotension or severe liver failure, or with any missing data required to complete the questionnaire are excluded

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with benign prostatic hyperplasia<br> | Drug: Tamsulosin<br> <br> * Other names: Secotex®;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with adverse events |  | up to 21 months |
Chronic Pain After Thoracotomy, an Incidence Study in a Single Surgical Center

Study Overview
=================
Brief Summary
-----------------
Investigation of chronic pain frequency after thoracotomy for lung cancer. Risk factors for development of chronic pain are investigated. Questionnaire survey.

Official Title
-----------------
Chronic Pain After Thoracotomy, an Incidence Study in a Single Surgical Center

Conditions
-----------------
Thoracotomy, Chronic Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: thoracotomized patients Exclusion Criteria: mental incapacity, poor understanding of French, pre-existing chronic pain before surgery, redo-surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain and pain score |  | one year postoperative |